We propose that substantial reductions in the morbidity and mortality of acute myocardial infarction can be achieved by new approaches aimed at preventing the iron-mediated damage that occurs during reperfusion of ischemic myocardium. Our major hypothesis is: Production of reactive oxygen species during reperfusion causes injury due to .OH production or other processes dependent upon availability of iron, which is determined by transferrin and ferritin regulation of the cellular labile iron pool. We will investigate, using molecular biological methods in cultured cardiac myocytes, the cellular regulation of free iron. We will then ascertain the degree to which free iron is involved in oxidant injury in cultured myocytes, and apply our findings to potential therapeutic interventions in isolated, perfused rabbit hearts.
In AIM 1, we will infect cultured adult rat cardiac myocytes with recombinant adenoviruses encoding constitutively expressed, unregulated, or inducible, iron- regulated, human transferrin receptors. We will examine the effect of infection with these adenoviruses on iron-transferrin uptake and cellular free iron and ferritin levels. Under conditions simulating oxidant exposure during reperfusion, we will measure cell injury, lipid peroxidation and glutathione oxidation, all of which we postulate will be increased in the genetically altered myocytes with unregulated transferrin receptors.
In AIM 2 we will study a group of unique, newly discovered iron chelators, the exochelins of Mycobacterium tuberculosis, which prevent .OH production and are both water and lipid soluble. These agents enter cells more rapidly than other chelators and have a very high binding affinity for iron. We anticipate that the exochelins will reduce intracellular iron levels and susceptibility to oxidant injury.
In AIM 3 we will examine in cultured myocytes and isolated perfused rabbit hearts several measures to reduce intracellular iron. In cultured myocytes we will study a receptor- dependent iron chelator, lactoferrin, and the effect of agents (chloroquine and ammonium chloride) that increase pH in endocytic vesicles and lysosomes, thereby inhibiting release of iron from transferrin and ferritin. In conjunction with these studies we will employ a new highly sensitive assay for .OH, which employs gas chromatography and mass spectrometry detection of salicylate isomers of this radical. Further studies of iron-directed potential therapies will measure ventricular function, myocardial enzyme release and lipid peroxidation in isolated hearts exposed to hypoxia and reoxygenation, using the chelators and other methods for reducing intracellular free iron which were previously examined in the experiments with cultured cardiac myocytes.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL055291-02
Application #
2332550
Study Section
Cardiovascular and Pulmonary Research A Study Section (CVA)
Project Start
1996-02-01
Project End
1999-01-31
Budget Start
1997-02-01
Budget End
1998-01-31
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Horwitz, Lawrence D; Horwitz, Marcus A (2014) The exochelins of pathogenic mycobacteria: unique, highly potent, lipid- and water-soluble hexadentate iron chelators with multiple potential therapeutic uses. Antioxid Redox Signal 21:2246-61
Ambler, S Kelly; Hodges, Yvonne K; Jones, Gayle M et al. (2008) Prolonged administration of a dithiol antioxidant protects against ventricular remodeling due to ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol 295:H1303-H1310
Pahl, Paula M B; Reese, Sara M; Horwitz, Lawrence D (2007) A lipid-soluble iron chelator alters cell cycle regulatory protein binding in breast cancer cells compared to normal breast cells. J Exp Ther Oncol 6:193-200
Hodges, Yvonne K; Weinberger, Howard D; Stephens, Janet et al. (2006) Desferri-Exochelin, a lipid-soluble, hexadentate iron chelator, effectively removes tissue iron. Transl Res 148:63-71
Hodges, Yvonne K; Reese, Sara M; Pahl, Paula M B et al. (2005) Paradoxical effects of iron chelation on growth of vascular endothelial cells. J Cardiovasc Pharmacol 45:539-44
Pahl, Paula M B; Horwitz, Lawrence D (2005) Cell permeable iron chelators as potential cancer chemotherapeutic agents. Cancer Invest 23:683-91
Hodges, Yvonne K; Antholine, William E; Horwitz, Lawrence D (2004) Effect on ribonucleotide reductase of novel lipophilic iron chelators: the desferri-exochelins. Biochem Biophys Res Commun 315:595-8
Horwitz, L D; Sherman, N A (2001) Bucillamine prevents myocardial reperfusion injury. J Cardiovasc Pharmacol 38:859-67
Pahl, P M; Horwitz, M A; Horwitz, K B et al. (2001) Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells. Breast Cancer Res Treat 69:69-79
Rosenthal, E A; Bohlmeyer, T J; Monnet, E et al. (2001) An iron-binding exochelin prevents restenosis due to coronary artery balloon injury in a porcine model. Circulation 104:2222-7

Showing the most recent 10 out of 17 publications